1[1]Uchibori M,Nishida Y,Nagasaka T,et al.Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.Int J Oncol,2006,1:33-42.
3[3]Hidalgo M,Eckhardt,SG.Development of matrix metalloproteinase inhibitors in cancer therapy.J Natl Cancer Inst,2001,2:178-193.
4[4]Henriet P,Blavier L,Declerck YA.Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation.APMIS,1999,107:111-119.
5[5]Ferrari C,Benassi S,Ponticelli F,et al.Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma:Findings in 42 patients followed for 1-16 years.Acta Orthop.Scand,2004,75:487.
6[6]Wang T,Yamashita K,Iwata K,et al.Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways.Biochem Biophys Res Commun,2002,296:201-205.
7[7]Liotta L A,and Kohn E C.The microenvironment of the tumour-host interface.Nature,2001,411:375.
9[9]Mannello F,Luchetti F,Falcieri E,et al.Multiple roles of matrix metalloproteinases during apoptosis.Apoptosis,2005,10:19-24.
10[10]Harisi R,Dudas J,Timar F,et al.Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix.Anticancer Res,2005,25:805-813.
